Establishment Labs Holdings Inc. (ESTA) - 10-K Summary
Business Context and Reporting Period
Company: Establishment Labs Holdings Inc.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: A global medical technology company focused on breast aesthetics and reconstruction, primarily through its Motiva Implants platform. The company manufactures silicone gel-filled breast implants in Costa Rica and sells them in over 100 countries. In September 2024, the company received FDA Premarket Approval (PMA) for Motiva Implants in the United States, commencing commercial sales in October 2024.
Key Developments:
- Launched "Preservé," a minimally invasive breast tissue-preserving technology, in February 2025.
- Published 3-year results of the Mia Femtech clinical study in October 2025, showing a 1% reoperation rate and high patient satisfaction.
- Completed construction of a new 100,000 sq. ft. manufacturing facility in Costa Rica in June 2024.
- CEO transition: Peter Caldini appointed CEO effective May 7, 2025, following the retirement of Juan José Chacón-Quirós.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $211,076 | $166,025 |
| Gross Profit | $146,308 | $109,525 |
| Gross Margin | 69.3% | 66.0% |
| Net Loss | $(51,064) | $(84,596) |
| Diluted Net Loss Per Share | $(1.72) | $(3.00) |
| Cash and Cash Equivalents (Year End) | $75,572 | $90,347 |
| Total Debt (Principal) | $246,367 | $221,367 |
| Accumulated Deficit | $(495,756) | $(444,692) |
Operating Expenses: Total operating expenses were $185.3 million in 2025, up from $159.5 million in 2024. Sales, General, and Administrative (SG&A) expenses increased to $165.1 million, while R&D expenses were $20.2 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 27.2% year-over-year, driven primarily by the U.S. market launch (generating $45.6 million in sales) and growth in EMEA (16.4%) and Latin America (14.1%). This was partially offset by a 28.6% decline in Asia-Pacific due to distributor inventory dynamics in China.
- Margin Expansion: Gross margin improved to 69.3% from 66.0%, attributed to higher selling prices in the U.S. market.
- Net Loss Reduction: Net loss narrowed significantly to $51.1 million from $84.6 million. This improvement was aided by a $6.4 million foreign currency transaction gain (vs. an $8.8 million loss in 2024) and the release of a $9.4 million valuation allowance on U.S. deferred tax assets.
- Debt Structure: The company advanced the Tranche D Term Loan of $25 million in September 2025, bringing total outstanding principal to $246.4 million. Interest expense increased to $25.3 million.
Guidance, Outlook, and Risks
Outlook: Management expects operating expenses to increase in 2026 due to continued commercial expansion in the U.S. and ongoing clinical study requirements. The company does not expect to be profitable in 2026. Demand remains sensitive to macroeconomic conditions, including inflation and consumer spending on elective procedures.
Key Risks and Contingencies:
- Supply Chain Concentration: The company relies on a single-source supplier, Avantor, for medical-grade silicone. Avantor has indicated it does not intend to allow the current master supply agreement to renew automatically, requiring negotiations for future terms.
- Regulatory Environment: Ongoing FDA post-approval study (PAS) requirements and potential changes in global regulatory frameworks (e.g., EU MDR amendments) pose compliance risks.
- Market Competition: Intense competition from larger entities (Allergan/AbbVie, Mentor/J&J, Sientra) with greater resources and established market share.
- Liquidity: While cash resources are sufficient for the next 12 months, the company has an accumulated deficit of $495.8 million and may require additional capital to fund growth and debt obligations.
Investor Verification Checklist
- U.S. Market Penetration: Verify the sustainability of U.S. revenue growth ($45.6M in 2025) and the rate of surgeon adoption post-FDA approval.
- Supply Agreement Renewal: Monitor the outcome of negotiations with Avantor regarding the medical-grade silicone supply contract expiring in 2026.
- Debt Covenants: Confirm continued compliance with the minimum liquidity covenant (raised to $30 million in September 2025) and gross sales targets under the Credit Agreement.
- Clinical Data: Review ongoing results from the Post-Approval Study (PAS) and long-term IDE study to ensure safety profiles remain favorable compared to competitors.
- China Market Recovery: Assess the timeline for recovery in the Asia-Pacific region, specifically China, where revenue declined significantly in 2025.